Capital Rx Drug Recall Report

JULY 2025

Welcome to the **Capital Rx Drug Recall Report**. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. Capital Rx is executing its mission through the deployment of Judi®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. Judi connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **7/16/2025****

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
6/18/2025	Class 2	Celecoxib 200 Mg Caps	Alembic Pharmaceuticals Limited	62332-0142-71	BATCH 2405014780, EXP 9/30/2027	The presence of foreign substance, a customer complaint found one Tadalafil 5mg tablet inside a sealed 500- count bottle of Celecoxib 200mg capsule
6/18/2025	Class 2	Cephalexin 125 Mg/5ml Susr	Ascend Laboratories, LLC	A) 67877-0544-88 B) 67877-0544-68	A) 23141828, 23141829, EXP 5/31/2025; 23142342, EXP 6/30/2025; 23142708, EXP 7/31/2025; 23144035, EXP 10/31/2025; 23144270, EXP 11/302025; 24140026, EXP 12/31/2025 B) 23142343, EXP 6/30/2025; 23143526, EXP 9/30/2025; 23144036, EXP 10/31/2025; 23144269, EXP 11/30/2025; 24140027, EXP 12/31/2025; 24144282, EXP 10/31/2026	Failing to meet impurity and degradation standards because Cephalexin Glucose Adduct was found in the medication

Capital Rx Drug Recall Report

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
7/2/2025	Class 2	Azelastine Hcl 0.05 % Soln	Apotex Corp.	60505-0578-04	VD1654, EXP 06/30/2027	A lack of assurance of sterility
7/2/2025	Class 2	Brimonidine Tartrate-Timolol 0.2-0.5 % Soln	Apotex Corp.	60505-0589-03	VC6058, EXP 10/31/2025	A lack of assurance of sterility
7/2/2025	Class 2	Ketorolac Tromethamine 0.5 % Soln	Apotex Corp.	60505-1003-02	TZ1236, EXP 11/30/2025	A lack of assurance of sterility
7/2/2025	Class 2	Metoclopramide Hcl 10 Mg Tabs	Teva Pharmaceuticals USA, Inc	00093-2203-01	5420094, EXP 09/30/2027	The presence of a foreign substance
7/2/2025	Class 2	Sodium Chloride 0.9 % Soln	B Braun Medical, Inc	00264-7800-10	J4L260, J4L261, J4L270, J4L271, J4L280, EXP 2/28/2027	A lack of assurance of sterility, there were tiny holes found in the finger boxes used during the packaging process, which can cause leaks
7/9/2025	Class 1	Penicillin G Potassium 20000000 Unit Sol	Sandoz Inc	00781-6136-94	PG4360, EXP. 11/30/2027	A labeling mix up. A complaint reported that Cefazolin vials incorrectly labelled as Penicillin G Potassium were included in a carton of Cefazolin vials
7/9/2025	Class 2	Gabapentin 100 Mg Caps	The Harvard Drug Group LLC	00904-6665-61	M05205, EXP 10/2026	A defective container, packaging may not be sealed correctly
7/9/2025	Class 2	Metoprolol Succinate Er 25 Mg Tb24	Granules Pharmaceuticals Inc	70010-0780-01, 70010-0780-05	A)1400008A, EXP 12/31/2025; B) 1400008B, EXP 12/31/2025	Failing to meet dissolution specifications, which may result in the tablets not dissolving properly
7/16/25	Class 2	Duloxetine Hcl 40 Mg Cpep	Breckenridge Pharmaceutical, Inc.	51991-0750-33	230199, EXP 01/31/2026	Failing to meet purity standards, an impurity called N-nitroso-duloxetine being higher than the acceptable limit

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Celecoxib 200 Mg Caps	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=213763
Class 2	Cephalexin 125 Mg/5ml Susr	A) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214017 B) https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214018
Class 2	Azelastine Hcl 0.05 % Soln	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214114
Class 2	Brimonidine Tartrate-Timolol 0.2-0.5 % Soln	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214115
Class 2	Ketorolac Tromethamine 0.5 % Soln	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214100
Class 2	Metoclopramide Hcl 10 Mg Tabs	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214032
Class 2	Sodium Chloride 0.9 % Soln	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214383
Class 2	Penicillin G Potassium 20000000 Unit Solr	https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/update-sandoz-inc-issues-voluntary-nationwide-recall-expansion-one-additional-lot-cefazolin
Class 2	Gabapentin 100 Mg Caps	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214440
Class 2	Metoprolol Succinate Er 25 Mg Tb24	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214622
Class 2	Duloxetine Hcl 40 Mg Cpep	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=214736